Cancer Invest.2021 Apr;39(4):285-296.doi: 10.1080/07357907.2021.1894570.Epub 2021 Mar 11.
2021-04-25Cancer Invest.2021 Apr;39(4):285-296.doi: 10.1080/07357907.2021.1894570.Epub 2021 Mar 11.The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.